TGA / PMDA / NMPA · Asia-Pacific
tablet — TGA / PMDA / NMPA regulatory status
tablet regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 1071 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 042011 | Phase 3 | George Institute for | 2024-512676-36-00 |
| 1245-0256 | Phase 3 | Boehringer Ingelheim | 2024-512577-27-00 |
| 1378-0041 | Phase 3 | Boehringer Ingelheim | 2025-521188-11-00 |
| 156-201-00307 | Phase 3 | Otsuka Beijing Research | 2023-508218-41-00 |
| 1821-FSH-301 | Phase 3 | Fulcrum Therapeutics | 2024-512737-33-00 |
| 19920 | Phase 3 | Bayer | 2023-504884-17-00 |
| 2.16/VI/22 | Phase 3 | Cardiol Therapeutics | 2023-503913-31-01 |
| 2019/ABM/01/00074 | Phase 3 | Bial Portela & | 2024-516714-37-00 |
| 20190009 | Phase 3 | Amgen | 2023-508214-42-00 |
| 20190172 | Phase 3 | Amgen | 2024-511187-81-00 |
| 20190529 | Phase 3 | Amgen | 2023-503435-17-00 |
| 202100617 | Phase 3 | Disc Medicine | 2023-508389-13-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12415794 | Pyridazinone compounds and uses thereof | US |
| 12318487 | Solid tablet dosage form of ridinilazole | US |
| 12240831 | Pyridazinone compounds and uses thereof | US |
| 12240833 | Pyridazinone compounds and uses thereof | US |
| 12060327 | Psychotropic agents and uses thereof | US |
| 12048691 | High dosage tebipenem pivoxil tablet formulation | US |
| 12012395 | Pyridazinone compounds and uses thereof | US |
| 11713295 | Psychotropic agents and uses thereof | US |
| 2022354866 | IMMEDIATE RELEASE MULTILAYER TABLET | US |
| 11390606 | Pyridazinone compounds and uses thereof | US |
| 11377421 | Psychotropic agents and uses thereof | US |
| 11253445 | Oxidative hair color remover in tablet or pellet form | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of tablet?
tablet currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get tablet regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to tablet?
This spoke lists 1071 published programs associated with tablet in our pipeline index.